SCYNEXIS, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
SCYNEXIS, Inc. (SCYX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $8.60 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2021-03-29
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.00.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.00.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.00.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $8.60, a 1492.59% increase from fiscal 2019.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $0.54.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was $0.00.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2017 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2020-12-31 | $8.60 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $8.60 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $8.60 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $0.54 10-K · filed 2020-03-11 | |||
| 2019-09-30 | $0.54 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-14 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-03-14 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-03-13 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-13 | |||
| 2014-12-31 | $20.40 10-K · filed 2016-03-07 | |||
| 2013-12-31 | $21.01 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |